The Evolution of Three Decades of Antiretroviral Therapy: Challenges, Triumphs and the Promise of the Future

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2014 Apr 16

PMID 24730660

Citations 82

Authors

Alice Tseng

Jason Seet

Elizabeth J Phillips

Affiliations

Soon will be listed here.

Abstract

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.

Citing Articles

Autophagy and Programmed Cell Death Modalities Interplay in HIV Pathogenesis.

Lamsira H, Sabatini A, Ciolfi S, Ciccosanti F, Sacchi A, Piacentini M Cells. 2025; 14(5).

PMID: 40072080 PMC: 11899401. DOI: 10.3390/cells14050351.

Medicine Meets Science: The Imperative of Scientific Research and Publishing for Physician-Scientists.

Bhaskar S Indian J Radiol Imaging. 2025; 35(Suppl 1):S9-S17.

PMID: 39802717 PMC: 11717469. DOI: 10.1055/s-0044-1800803.

Effect of in vitro exposure of first-line antiretrovirals on healthy human spermatozoa on kinematics and motility.

Pinto S, Aneck-Hahn N Int Urol Nephrol. 2025; .

PMID: 39753908 DOI: 10.1007/s11255-024-04340-x.

Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.

Jemal M, Ashenef B, Sinamaw D, Adugna A, Getinet M, Baylie T J Int Assoc Provid AIDS Care. 2024; 23:23259582241303305.

PMID: 39665219 PMC: 11635881. DOI: 10.1177/23259582241303305.

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir.

Gonzalez-Navarro I, Urrea V, Galvez C, Garcia-Guerrero M, Moron-Lopez S, Puertas M J Clin Invest. 2024; 135(2.

PMID: 39610346 PMC: 11735095. DOI: 10.1172/JCI183952.

References

Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26. PMC: 2854555. DOI: 10.1056/NEJMoa0807252. View

Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F . Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003; 17(8):1157-65. DOI: 10.1097/00002030-200305230-00007. View

Zeldin R, Petruschke R . Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2003; 53(1):4-9. DOI: 10.1093/jac/dkh029. View

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

Wensing A, van Maarseveen N, Nijhuis M . Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 2009; 85(1):59-74. DOI: 10.1016/j.antiviral.2009.10.003. View

Emamzadeh-Fard S, Fard S, SeyedAlinaghi S, Paydary K . Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review. Infect Disord Drug Targets. 2012; 12(5):346-56. DOI: 10.2174/187152612804142251. View

Thurman A, Clark M, Hurlburt J, Doncel G . Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health. 2013; 5:695-708. PMC: 3808127. DOI: 10.2147/IJWH.S34030. View

Phillips E, Chung W, Mockenhaupt M, Roujeau J, Mallal S . Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011; 127(3 Suppl):S60-6. PMC: 3061439. DOI: 10.1016/j.jaci.2010.11.046. View

Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J . Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013; 47(11):1429-39. DOI: 10.1177/1060028013504075. View

10.

Rendon A, Nunez M, Jimenez-Nacher I, Gonzalez de Requena D, Gonzalez-Lahoz J, Soriano V . Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med. 2005; 6(5):360-5. DOI: 10.1111/j.1468-1293.2005.00321.x. View

11.

Foisy M, Yakiwchuk E, Chiu I, Singh A . Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008; 9(6):389-96. DOI: 10.1111/j.1468-1293.2008.00579.x. View

12.

Gandhi R, Bosch R, Aga E, Albrecht M, Demeter L, Dykes C . No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis. 2009; 201(2):293-6. PMC: 2887684. DOI: 10.1086/649569. View

13.

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

14.

Mukonzo J, Owen J, Ogwal-Okeng J, Kuteesa R, Nanzigu S, Sewankambo N . Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One. 2014; 9(1):e86919. PMC: 3909010. DOI: 10.1371/journal.pone.0086919. View

15.

Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A . Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011; 66(9):2107-11. DOI: 10.1093/jac/dkr248. View

16.

Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J . Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2006; 21(1):41-6. DOI: 10.1097/QAD.0b013e328011d7c1. View

17.

Xu L, Liu H, Hong A, Vivian R, Murray B, Callebaut C . Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350). Bioorg Med Chem Lett. 2014; 24(3):995-9. DOI: 10.1016/j.bmcl.2013.12.057. View

18.

Fletcher C, Anderson P, Kakuda T, Schacker T, Henry K, Gross C . Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002; 16(4):551-60. DOI: 10.1097/00002030-200203080-00006. View

19.

Eron J, Young B, Cooper D, Youle M, DeJesus E, Andrade-Villanueva J . Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010; 375(9712):396-407. DOI: 10.1016/S0140-6736(09)62041-9. View

20.

Pennings P . HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep. 2014; 5(Suppl 1):e5. PMC: 3892620. DOI: 10.4081/idr.2013.s1.e5. View